Clinical Trials on Sick Leave in Belgium

Total 22 results

KU Leuven
National Institute for Health and Disability Insurance (NIHDI), Belgium; Haute...

Recruiting

The Effectiveness of a Functional Capacity Evaluation Among Persons on Sick Leave or Work Disability (FCE)

Absenteeism | Return to Work | Sick Leave

Belgium
Pfizer

Completed

Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

Encephalitis, Tick-borne

Belgium
Pfizer

Completed

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

Encephalitis, Tick-borne

Belgium
Imelda Hospital, Bonheiden

Completed

Second Study on Cardio-neuromodulation in Humans (CardNMH2)

Syncope | Syncope, Vasovagal | Cardiac Disease | Sick Sinus Syndrome

Belgium
Genzyme, a Sanofi Company

Completed

A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Sphingomyelin Lipidosis

United States, Belgium, Brazil, France, Germany, Italy, United Kingdom
Medtronic Bakken Research Center

Completed

PANORAMA Observational Study

Heart Failure | Heart Block | Arrhythmia | Sinus Node Disease

Belgium, Russian Federation, Former Serbia and Montenegro, India, Kuwait, Saudi Arabia
Boston Scientific Corporation

Completed

Ingenio Device Algorithm Study (IVORY)

Heart Failure | AV Block | Sinus Node Disease

Denmark, United Kingdom, Spain, Hong Kong, Netherlands, Sweden, Malaysia, Austria, Belgium, France, Germany, Italy
Pfizer

Completed

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

Lyme Borreliosis

United States, Germany, Belgium
Pfizer
Valneva Austria GmbH

Completed

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Lyme Borreliosis, Nervous System

Belgium, United States
Boston Scientific Corporation

Completed

Safety and Performance Study of the INGEVITY Lead

Bradycardia | Sinus Node Dysfunction

United States, Belgium, Germany, Canada, Spain, Sweden, Italy, Malaysia, Denmark, Australia, Austria, United Kingdom, Hong Kong, France, Portugal, Thailand
LivaNova

Completed

Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease

Sinus Node Dysfunction | Brady Tachy Syndrome

United States, France, Belgium, Germany, United Kingdom, Italy, Monaco, Spain
Genzyme, a Sanofi Company

Completed

Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency (ASCEND)

Sphingomyelin Lipidosis

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Chile, France, Germany, Italy, Japan, Netherlands, Portugal, Spain, Tunisia, Turkey, United Kingdom
LivaNova

Completed

Spontaneous Atrio Ventricular Conduction Preservation (SAVER)

Sinus Node Dysfunction | Bradycardia-Tachycardia Syndrome | Paroxysmal Atrioventricular Block

United Kingdom, France, Germany, Belgium, Italy
Sanofi

Completed

A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)

Sphingomyelin Lipidosis

Italy, Czechia, Belgium, France, Portugal, Turkey, United States, Argentina, Brazil, Chile, Germany, Romania, Spain
Prevail Therapeutics
Eli Lilly and Company

Recruiting

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM)

Frontotemporal Dementia

United States, Australia, Belgium, Spain, United Kingdom, France
FORUM Pharmaceuticals Inc

Unknown

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Granulin Mutation

Belgium, United States, France, Italy, Netherlands, United Kingdom
CENTOGENE GmbH Rostock

Active, not recruiting

Epidemiological Study in FRONtoTemporal Dementia (EFRONT)

Frontotemporal Dementia

Italy, Spain, Belgium, Turkey, Portugal, Germany, Greece
Denali Therapeutics Inc.
Takeda

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

Frontotemporal Dementia

Spain, Turkey, France, Belgium, Netherlands, Portugal, Italy, Colombia, Czechia, Brazil, United Kingdom, Serbia
Wave Life Sciences Ltd.

Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

ALS | FTD

Canada, Belgium, New Zealand, Netherlands, Australia, Sweden, United Kingdom, Ireland
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Amyotrophic Lateral Sclerosis | Frontotemporal Dementia

Spain, United States, Belgium, France, Germany
Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
TauRx Therapeutics Ltd

Terminated

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Alzheimer's Disease | Behavioral Variant Frontotemporal Dementia

Korea, Republic of, United States, Spain, Taiwan, Canada, Belgium, Malaysia, United Kingdom, Australia, Singapore, Croatia, Finland, France, Germany, Netherlands, Romania, Russian Federation

Clinical Trials on Sick Leave in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations